New strategies accelerate the path to overcome refractory interstitial cystitis

Li, Yiu‐Tai; Chang, Wen-Hsun; Wang, Peng-Hui

doi:10.1097/jcma.0000000000000733

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…25,26 There are many strategies applicable to DM control, such as lifestyle modification, routine and continuous blood glucose monitoring, and pharmacological therapy (antidiabetic agents [ADA] and sugar-lowering drugs), [27][28][29][30] and all of them attempt to minimize DM-related adverse events (AEs) and maintain the quality of life, similar to the therapy for other troublesome diseases by multiple modality strategy. [31][32][33] In fact, all aforementioned strategies are essential and critical, although some recommendations favoring strategies step by step are proposed. 34,35 However, sometimes, to obtain the optimal sugar control, monotherapy or in a combination of others is needed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases

Lee

Wang

Yang

et al. 2022

Journal of the Chinese Medical Association

Self Cite

View full text Add to dashboard Cite

Type 2 diabetes mellitus (DM) is characterized by inability of faulty pancreatic β-cells to secret a normal amount of insulin to maintain normal body consumption, and/or peripheral tissue has a decreased susceptibility to insulin, resulting in hyperglycemia and insulin resistance. Similar to other chronic systemic inflammatory diseases, DM is a result from dysregulated interactions between ethnic, genetic, epigenetic, immunoregulatory, hormonal, and environmental factors. Therefore, it is rational to suppose the concept as “To do one and to get more”, while using antidiabetic agents (ADA), a main pharmacologic agent for the treatment of DM, can provide an extraglycemia effect on comorbidities or concomittent comorbidities to DM. In this review, based on the much strong correlation between DM and metabolic dysfunction-associated fatty liver diseases (MAFLD) shown by similar pathophysiological mechanisms and a high prevalence of DM in MAFLD and its vice versa (a high prevalence of MAFLD in DM), it is possible to use the strategy to target both diseases simultaneously. We focus on a new classification of ADA, such as glucagon-like peptide-1 receptor (GLP1R) agonist and sodium-glucose cotransporter-2 (SGLT-2) inhibitors to show the potential benefits of extraglycemic effect on MAFLD. We conclude that the management of DM patients, especially for those who need ADA as adjuvant therapy should include healthy lifestyle modification to overcome the metabolic syndrome, contributing to the urgent need of an effective weight-reduction strategy. GLP1R agonist is one of effective body weight-lowering medications, which may be a better choice for DM complicated with MAFLD or its-associated severe form as metabolic associated steatohepatitis (MASH), although the role of SGLT-2 inhibitors is also impressive. The prescription of these two classes of ADA may satisfy the concept “To do one and to get more”, based on successful sugar-lowering effect for controlling DM and extraglycemia benefits of hepatoprotective activity in DM patients.

show abstract